Pancreatic Cancer is one of the most lethal cancers due to over 90% of cases being diagnosed at an advanced, incurable stage
While overall 5-year survival of metastatic pancreatic cancer is <5%, outcomes dramatically improve when it is detected early.
Since development of metastatic pancreatic cancer from its precursor lesions may take up to 20 years, there is a large window of opportunity for earlier detection.
Using our Next-gen Biomarker DiscoveryPlatform, combined with Innovative 'Big Data' Omics, BiomaRx is developing a multi-analyte liquid biopsy.
This carries the potential to be the first ever non-invasive biomarker set to accurately detect pancreatic cancer before it becomes invasive and distinguish between patients with and without advanced pancreatic cancer.
Our diagnostic test will shift the detection of pancreatic cancer to an earlier stage when therapeutic intervention is a viable option.
Developed at Harvard Medical School, biomaRx has applied a disruptive, proprietary systems biology engine to identify and deliver first-in-class therapeutics for high priority drug targets in pancreatic cancer.